Oncotype SEQ Liquid Select

Transforming the Management of Cancer with Non-Invasive Liquid Biopsy Tests

Oncotype SEQ Liquid Select is a liquid biopsy mutation panel that uses next-generation sequencing to identify and assess actionable genomic alterations of select 17 genes to help personalize treatment of patients with stage IV solid tumor cancer, including lung, breast, colon, melanoma, ovarian or gastrointestinal stromal tumor (GIST). As a clinically actionable blood-based panel, Oncotype SEQ is designed to help meet the needs of oncologists by delivering insights into targeted therapy options for the more than 350,000 cancer patients who recur or present with late-stage disease each year in the United States.

The test was developed to detect specific genomic alterations to help doctors and patients evaluate treatment options based on select genomic cancer markers that have either been included in National Comprehensive Cancer Network (NCCN®) guidelines, associated with sensitivity or resistance to relevant FDA approved therapies, or established as eligibility criteria for currently enrolling Phase II-IV clinical trials.

Based on successful completion of our analytical validation study, Oncotype SEQ is now commercially available under CLIA. The results of the analytical validation study are being submitted for presentation at a major medical meeting. Additionally, we have begun our clinical concordance study to establish further evidence to support reimbursement. Our unique experience of delivering molecular tests into clinical practice through our world-class commercial channel - including strong relationships with community physicians, combined with our expertise in demonstrating clinical utility and gaining reimbursement for value-based tests - positions us to make a significant impact in this emerging field of liquid biopsy.


Learn more about Genomic Health

Oncotype DX My Colon Cancer Coach